NCT03404791View on ClinicalTrials.gov

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

December 23, 2019

Study Completion Date

September 15, 2022

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG

TAR-200

TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.

Trial Locations (12)

14642

University of Rochester, Rochester

21076

Chesapeake Urology Research Associates, Hanover

23462

Urology of Virginia, PLCC, Virginia Beach

28041

Hosp. Univ. 12 de Octubre, Madrid

30720

North Georgia Urology Center, Dalton

37209

Urology Associates, PC, Nashville

37232

Vanderbilt University Medical Center, Nashville

46009

Inst. Valenciano de Oncologia, Valencia

48084

Michigan Institute of Urology, Troy

78750

North Austin Urology, Austin

85054

Mayo Clinic Arizona, Phoenix

08025

Fund. Puigvert, Barcelona

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03404791 - A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy | Biotech Hunter | Biotech Hunter